Transaction · 0001352620-26-000006

Hasnain Faheem

Hasnain Faheem, PRES, CEO, reported a transaction classified as grant at Gossamer Bio, Inc. involving 5800051.000000 shares for an estimated $0.00. Reported holdings after the transaction were 5800051.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code APRES, CEO
GOSSGossamer Bio, Inc.
Filing timeAug 26
Trade dateAug 24, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
Pre-filing
Returns since

GOSS price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
GOSS since 2026-08-26Filed 9 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001352620-26-000006
Stock Option (Right to Buy)
Transaction date
Aug 24, 2026
Filed Aug 26, 2026, 10:08 PM · 2d delay
Shares
5.80M sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
5.80M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Increase
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President & CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the I…

  2. F2

    The Pre-Funded Warrant has no expiration date and is exercisable immediately. Prior to the Issuer obtaining Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of Series A-1…

  3. F3

    50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the…

Original filing · 0001352620-26-000006
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

GOSS